Bladder cancer
Managing adverse events of systemic therapies in muscle-invasive and metastatic UCa
Objectif pédagogique: Gain practical knowledge on the management of treatment-related adverse events (AEs) and their impact on anticancer treatment strategies in muscle-invasive and metastatic UCa.
Spécialité: Medical oncology, urology, clinical oncology
Public cible: Specialists (CME: basic, intermediate), Residents (senior)
Dernière mise à jour: August 2026
Contexte:
Regulatory approval status of drugs included in this topic (indications limited to the metastatic UCa setting, status 9 July 2026))
ChT: chemotherapy; CPS: combined positive score; PD-(L)1: programmed death-(ligand) 1
In all cases presented in this topic, it is assumed that the relevant antibodies/tests are used for PD-L1 and FGFR testing.
This educational platform includes case challenges with treatment options that may not be indicated for this use in your country. Please refer to your local prescribing information.